Vir Biotechnology (VIR) Free Cash Flow (2018 - 2026)
Vir Biotechnology (VIR) reported Free Cash Flow of -$132.8 million for Q1 2026, down 66.5% on a YoY basis from -$396.4 million in Q1 2025, and down 406.31% sequentially from -$26.2 million in Q4 2025.
Vir Biotechnology (VIR) Free Cash Flow (2018 - 2026) Analysis & Trends
Vir Biotechnology (VIR) has 9 years of Free Cash Flow data on file, last reported at -$132.8 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow fell 66.5% year-over-year to -$132.8 million; the trailing twelve-month figure through Mar 2026 stood at -$449.6 million (down 6.52% YoY), and the FY2025 full-year result was -$396.6 million, up 12.57% from the prior year.
- Free Cash Flow declined to -$132.8 million in Q1 2026, from -$26.2 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $939.5 million in Q2 2022 to a low of -$398.7 million in Q2 2023.
- A 5-year average of -$11.1 million and a median of -$109.5 million in 2023 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow jumped 694.22% in 2022 and tumbled 585.38% in 2023, its largest moves.
- Tracing VIR's Free Cash Flow over 5 years: stood at $22.6 million in 2022, then plunged by 585.38% to -$109.5 million in 2023, then gained by 18.12% to -$89.6 million in 2024, then surged by 70.74% to -$26.2 million in 2025, then plunged by 406.31% to -$132.8 million in 2026.
- Business Quant data shows VIR's Free Cash Flow at -$132.8 million in Q1 2026, -$26.2 million in Q4 2025, and -$167.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Vir Biotechnology | 1.38 Bn | 1.38 Bn | - | -132.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -132.78 Mn |
| Mar 31, 2026 | -132.78 Mn |
| Dec 31, 2025 | -26.22 Mn |
| Dec 31, 2025 | -26.22 Mn |
| Sep 30, 2025 | -167.89 Mn |
| Sep 30, 2025 | -167.89 Mn |
| Jun 30, 2025 | -122.76 Mn |
| Jun 30, 2025 | -122.76 Mn |
| Mar 31, 2025 | -79.75 Mn |
| Mar 31, 2025 | -79.75 Mn |
| Dec 31, 2024 | -89.63 Mn |
| Dec 31, 2024 | -89.63 Mn |
| Sep 30, 2024 | -174.25 Mn |
| Sep 30, 2024 | -174.25 Mn |
| Jun 30, 2024 | -78.51 Mn |
| Jun 30, 2024 | -78.51 Mn |
| Mar 31, 2024 | -111.26 Mn |
| Mar 31, 2024 | -111.26 Mn |
| Dec 31, 2023 | -109.46 Mn |
| Dec 31, 2023 | -109.46 Mn |